Intelligent Biotherapeutic Development

InnoTherapix develops transfer-ready biopharmaceutical technologies through cell-line engineering, antibody development, formulation science, and regulatory-focused project execution.

Explore Our Capabilities Discuss Your Project

ABOUT INNOTHERAPIX

Turning Biopharmaceutical Concepts Into Transfer-Ready Technologies

InnoTherapix is a biotechnology development company specializing in biosimilar and biobetter cell lines, recombinant biotherapeutics, peptide formulations and technology-transfer projects. We integrate scientific development, regulatory strategy and manufacturing-oriented design to help partners advance efficiently from concept to implementation.

Discover InnoTherapix

Services

InnoTherapix provides integrated biopharmaceutical development and technology-transfer services. Integrated scientific, technical, and strategic services that advance biopharmaceutical projects from early development to scalable implementation and technology transfer.

Explore Services

Technologies

Development and optimization of mammalian and microbial expression systems for therapeutic proteins, antibodies, biosimilars, and other recombinant products.

Computationally guided engineering of therapeutic antibodies to support humanization, candidate selection, developability, and biobetter development.

Formulation technologies designed to improve peptide stability, delivery, manufacturability, and therapeutic performance across oral and injectable dosage forms.

Technology-development and transfer solutions for biosensor products, with a particular focus on continuous glucose monitoring systems and their associated components.

Conceptual design of manufacturing facilities and production lines aligned with product requirements, process flow, GMP principles, and future scale-up.

Development of commercially viable oral solid pharmaceutical products supported by formulation design, process development, analytical planning, and registration strategy.

Projects

mAb AI-Derived Humanization

AI-driven humanization applies computational sequence and structural analysis to redesign non-human monoclonal antibodies while preserving target-binding characteristics. The process supports reduced immunogenicity risk and improved developability, stability, and expression. Selected candidates are prioritized for experimental evaluation and further biopharmaceutical development.

More Information